Latest HVIVO Press Release: 19.09.19 Unaudited Interim Results for the Six Months Ended 30 June 2019
MENUMENU
  • Services
        • Human challenge full-service solution
        • human challenge full service solution

          Industry leading provider of viral challenge studies

          • See Our Solution
        • hVIVO Challenge Models
          • Influenza
          • RSV
          • HRV
          • Asthma
          • COPD
          • Cough
        • Laboratory Services
          • Virology
          • Immunology
          • Biomarkers
  • Investors

        • Investors

          hVIVO’s shares are listed on the AIM market of the London Stock Exchange under the HVO ticker.

          This area is dedicated to keeping shareholders and potential investors informed.

        • Regulatory News
        • Presentations & Webcasts
        • Financial Reports
        • Financial Calendar
        • Governance
        • Shareholder Information
        • Share Price Info
        • Analyst Coverage
        • Advisers
        • Aim Rule 26
        • RNS Email Alerts
  • News, Media & Events

        • News, Media & Events

          A source for the latest press releases, scientific publications and other media as well as details of investor and scientific events that we attend and host across the world.

        • Press Releases
        • Other Company News
        • Videos
        • Events
  • About Us

        • About Us

          Our Mission is to build a profitable clinical development services business supporting product development for our clients through human challenge studies to establish early proof of concept.

          • More about hVIVO
        • Overview
        • Board of Directors
        • Executive Leadership Team
        • Imutex Joint Venture
        • Scientific Papers / Abstracts
        • Quality Commitment
        • Ethics & Compliance
        • img

          LATEST PRESS RELEASE

          06.08.19 hVIVO Successfully Completes RSV Challenge Study in Older Adults

        • UPCOMING EVENTS

          World Vaccine Congress Europe 201929 Oct - 31 Oct, Barcelona, Spain, Palau de Congressos de Catalunya
  • Volunteers
  • Careers
  • Contact Us

Visterra bringing influenza immunotherapy into Phase 2 with $30M cash influx

October 3, 2014 10:46 am

https://medcitynews.com/2014/10/visterra-bringing-influenza-immunotherapy-phase-2-30m-cash-influx/

Follow @hVIVO_UK

Comments are closed here.

Whether you’re a potential customer, job seeker, health professional or an investor, you can find the best way to contact us from the list below.

Contact Us
  • Terms & Conditions
  • Careers
  • Sitemap
© 2019 Copyright hVIVO Services Limited. All rights reserved.
Privacy Policy | Cookie Policy